SARCODO - Evaluation of coagulopathy and endothelial dysfunction as a predictive factor for the severity of SARS-CoV-2/COVID-19 infection

Head :SMADJA David, UMR-S1140 and Biosurgical Research Laboratory (Carpentier Foundation)

Last update : 05/05/2021 | Version : 1 | ID : 73746

General

Identification

Detailed name	Evaluation of coagulopathy and endothelial dysfunction as a predictive factor for the severity of SARS-CoV-2/COVID-19 infection
Sign or acronym	SARCODO
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	CPP2020-04-048b

General Aspects

Medical area	Biology Hematology Infectious diseases
Study in connection with Covid-19	Yes
Keywords	von Willebrand factor, endothelium, COVID-19, haemostasis

Scientific investigator(s) (Contact)

Name of the director	SMADJA
Surname	David
Address	HEGP, Service d'hématologie, 20 rue Leblanc, 75015 Paris
Phone	33613838972
Email	david.smadja@aphp.fr
Unit	UMR-S1140 and Biosurgical Research Laboratory (Carpentier Foundation)

Organization	Inserm
Collaborations	
Funding	
Funding status	Public
Details	ANR SARCODO (France Foundation)
Governance of the database	
Sponsor(s) or organisation(s) responsible	AP-HP
Organisation status	Public
Presence of scientific or steering committees	No
Additional contact	
Email	yannick.vacher@aphp.fr
Main features	
Type of database	
Type of database	Others
Specify	Clinical and laboratory database
Database recruitment is carried out as part of an interventional study	No
Database objective	
Main objective	Study the coagulopathy, vascular lesion and markers for tissue distress to characterise the exacerbation of patients with COVID-19 and identify patient populations who will develop or experience exacerbation of a thromboembolic or microvascular process, but also require curative anticoagulation.
Inclusion criteria	Patients aged at least 18 years Hospitalised in an intensive care or medicine department for suspected COVID-19. Patients covered by a social security regime (other than the state welfare scheme) Patient having been informed of the study and having given their informed consent in writing, or

	for whom a family member/trusted person has given their agreement
Population type	
Age	Adolescence (13 to 18 years) Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	General population
Pathology	
Gender	Male Woman
Geography area	Regional
French regions covered by the database	Île-de-France
Detail of the geography area	HEGP and Cochin Hospital
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2020
Size of the database	
Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	1000
Data	
Type of data collected	Clinical data Biological data
Clinical data (detail)	Direct physical measures Medical registration
Presence of a biobank	Yes
Contents of biobank	Whole blood

	Plasma Blood cells isolated DNA
Procedures	
Followed pathology	
Promotion and access	
Promotion	
Link to the document	2020- Debuc et al- SCRR Covid19.pdf
Link to the document	2020- Smadja_Article_Angiopoietin-Covid19-Angiogenesis.pdf
Link to the document	2020- diehl et al- AIC-covid19.pdf
Link to the document	2020- Khider et al-CEC JTH.pdf
Link to the document	2020- Petrazzuolo et al- Oncoimmunology COVID FRP.pdf
Link to the document	2020- bastard et al- Science AutomAb IFN Covid.pdf
Link to the document	2021- Philippe_et_al-Angiogenesis-WILLEBRAND.pdf
Link to the document	2021- Planquette et al- TR- EP Covid.pdf
Link to the document	2020- Guerin et al- SCRR-Article_MultidimensionalProteomicAppro.pdf
Link to the document	2020- Goudot et al- tropo covid-Front Med.pdf
Access	